3 General advice for managing COVID-19 symptoms
We will review and update these recommendations on a regular basis.
3.1 When managing COVID‑19 symptoms, take into account:
that not all patients will have COVID‑19
the patient's underlying health conditions, severity of the acute illness, whether they are taking multiple medicines, and the effect of COVID-19 on medicines. For example, supratherapeutic anticoagulation has been reported during the COVID-19 pandemic in some patients taking vitamin K antagonists such as warfarin (see the MHRA advice on warfarin and other anticoagulants – monitoring of patients during the COVID-19 pandemic). [amended 13 October 2020]
that older patients with comorbidities, such as chronic obstructive pulmonary disease (COPD), asthma, hypertension, cardiovascular disease and diabetes, may have a higher risk of deteriorating and need monitoring or more intensive management, including hospital admission
that patients with severe symptoms of COVID‑19 may deteriorate rapidly and need urgent hospital admission (see the NICE COVID-19 rapid guideline on managing suspected or confirmed pneumonia in adults in the community).
3.2 When managing key symptoms of COVID‑19 in the last hours and days of life, follow the relevant parts of NICE guideline on care of dying adults in the last days of life. This includes pharmacological interventions and anticipatory prescribing. Note that symptoms can change, and patients can deteriorate rapidly in a few hours or less.